

# PEER PERSPECTIVES

## IN THE TREATMENT OF ALL

ISSUE 3

ALL

### INSIDE THIS ISSUE:

- Reviewing the role of asparaginase therapy in the treatment of AYA patients with ALL/LBL
- Discussing AYA as a special population with unique treatment challenges, including perceptions of greater toxicities with asparaginase use
- Emphasizing the importance of using asparaginase-based protocols in AYA patients on clinical outcomes
- Exploring the efficacy, safety, and dosing schedules for an ALL/LBL asparaginase treatment option

### FEATURING

**Leidy Isenalumhe, MD, MS<sup>a</sup>**  
Director of Clinical Operations  
in the Department of  
Hematologic Malignancies,  
Moffitt Cancer Center,  
Tampa, Florida

“Asparaginase has been used in pediatric-based regimens for a very, very long time.<sup>1</sup> It is actually one of the backbones for ALL treatment.<sup>1</sup> Data have shown us that giving asparaginase-based regimens to adolescents and young adults helps with improving overall disease-free survival rates.<sup>2,3</sup>”

— Leidy Isenalumhe MD, MS

## Peer Perspectives in ALL: Asparaginase Therapy in AYA Patients

ALL=acute lymphoblastic leukemia; AYA=adolescents and young adults; B-ALL=B-cell acute lymphoblastic leukemia; CI=confidence interval; DFS=disease-free survival; *E. coli*=*Escherichia coli*; IM=intramuscular; LBL=lymphoblastic lymphoma; NCI=National Cancer Institute; NSAA=nadir serum asparaginase activity; PEG=polyethylene glycol; Q48=every 48 hours; U=unit.

<sup>a</sup>Leidy Isenalumhe is a paid consultant of Jazz Pharmaceuticals. This content is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment. The views and opinions expressed in this article are those of the author and Jazz Pharmaceuticals and do not necessarily reflect the opinions of the Moffitt Cancer Center.